CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

To join this study, adults must have specific types of advanced solid cancers that are locally advanced or have spread. They should generally be well enough to take part, meaning they have a life expectancy of at least three months and are able to carry out most daily activities without too much difficulty. Their body's organs, like the liver and kidneys, need to be working well, and they should have signs of cancer that can be measured by doctors.

The study is looking for people whose cancer has either not responded to, or who cannot take, standard treatments. This includes people with liver cancer, gallbladder or bile duct cancer, womb cancer, cervical cancer, ovarian cancer, stomach or gullet cancer, bowel cancer, and a type of lung cancer called non-small cell lung cancer.

There are also reasons why someone might not be able to join. For example, if they have had other cancers recently, certain serious heart problems, active infections, or uncontrolled autoimmune diseases. Also, people who have had significant side effects from previous treatments or who recently had major surgery might not be suitable.

If you join this study, it will involve several stages. First, there will be a 'screening' period where doctors will check if you meet all the requirements. If you do, you will then enter the 'treatment period,' which could last up to two years. During this time, you will receive the study drug, CR-001.

Throughout the treatment period, you'll have regular visits for medical checks and safety assessments. This will include scans to see how your cancer is responding, and blood tests to check your general health and how the drug is working in your body. Even after you stop taking the treatment, you'll continue to have follow-up visits, including scans to monitor your cancer until it shows signs of getting worse. You will also have long-term follow-up calls every three months to check on your health and survival.